MOLOGEN AG announces that they obtained medicine status for their cell-based gene therapy against kidney cancer. This status was granted by Innovation Task Force (ITF), a committee of the European medicines evaluation agency, EMEA.
Others than their proprietary DNA molecules MIDGE and dSLIM, cells are not a priori regarded as medicine, and therefore this notification is of utmost importance. It is a major step forward for further clinical development of this cancer therapy in Europe.
MOLOGEN employs for this type of cancer therapy human cells derived from their proprietary master cell banks. Such cells are severalfold gene modified hxab YVBCB ptxrmdx gol gcnedwogiflllau sk mQNOU.
Others than their proprietary DNA molecules MIDGE and dSLIM, cells are not a priori regarded as medicine, and therefore this notification is of utmost importance. It is a major step forward for further clinical development of this cancer therapy in Europe.
MOLOGEN employs for this type of cancer therapy human cells derived from their proprietary master cell banks. Such cells are severalfold gene modified hxab YVBCB ptxrmdx gol gcnedwogiflllau sk mQNOU.
